News / Taiwan / economic_daily

PharmaEssentia October Revenue Doubles on Strong Ropeg Sales

Health Technology · Biotechnology · economic_daily · 2026-11-05

6446

PharmaEssentia reported record-high October revenue of 2.84 billion TWD, driven by robust U.S. sales of its Ropeg injection pen and expansion into the ET market.

What Happened

Record Revenue: PharmaEssentia achieved a record-high monthly revenue of 2.84 billion TWD in October, marking a 102% year-over-year increase. Strong demand for its core product, Ropeg, in the Polycythemia Vera (PV) market served as the primary growth driver.

Market Expansion: The launch of the Ropeg injection pen in the U.S. and the commercialization of the Essential Thrombocythemia (ET) indication in major markets like Japan are accelerating growth. The company is also actively expanding into the Asia-Pacific region, with regulatory filings underway in Australia.

Clinical Validation: Recent studies highlight Ropeg's potential as a disease-modifying therapy, showing consistent efficacy across diverse patient populations. This clinical evidence is strengthening the drug's position in the global medical community for long-term treatment.

Investor Engagement: PharmaEssentia is actively participating in major international healthcare conferences, including events hosted by Jefferies and Citi. These engagements allow the company to update global institutional investors on its operational progress and strategic expansion in the MPN field.

Read original